Your browser is no longer supported. Please, upgrade your browser.
Settings
BPTH Bio-Path Holdings, Inc. daily Stock Chart
BPTH [NASD]
Bio-Path Holdings, Inc.
Index- P/E- EPS (ttm)-0.08 Insider Own8.59% Shs Outstand101.37M Perf Week8.95%
Market Cap96.09M Forward P/E- EPS next Y-0.11 Insider Trans0.00% Shs Float93.38M Perf Month4.89%
Income-6.80M PEG- EPS next Q-0.03 Inst Own18.40% Short Float3.08% Perf Quarter-30.30%
Sales- P/S- EPS this Y-20.30% Inst Trans2.86% Short Ratio18.69 Perf Half Y-43.91%
Book/sh0.10 P/B9.48 EPS next Y-22.20% ROA-67.90% Target Price3.25 Perf Year-36.81%
Cash/sh0.11 P/C8.50 EPS next 5Y- ROE-81.50% 52W Range0.81 - 3.19 Perf YTD-29.79%
Dividend- P/FCF- EPS past 5Y-7.10% ROI- 52W High-70.29% Beta2.44
Dividend %- Quick Ratio14.30 Sales past 5Y- Gross Margin- 52W Low16.74% ATR0.07
Employees11 Current Ratio14.30 Sales Q/Q- Oper. Margin- RSI (14)47.99 Volatility7.83% 8.37%
OptionableNo Debt/Eq0.00 EPS Q/Q2.30% Profit Margin- Rel Volume1.23 Prev Close0.95
ShortableYes LT Debt/Eq0.00 EarningsMar 15 AMC Payout- Avg Volume153.90K Price0.95
Recom2.00 SMA204.57% SMA50-12.40% SMA200-38.97% Volume190,057 Change-0.24%
Aug-10-16Reiterated Maxim Group Buy $5 → $2
Apr-18-16Initiated Rodman & Renshaw Buy $5
Jun-02-14Resumed Maxim Group Buy $5
May-09-14Initiated Maxim Group Buy $5
Feb-08-17 03:24PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Feb-07-17 08:00AM  Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
Dec-16-16 12:22PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosu
Dec-15-16 09:03PM  How Noodles & Co (NDLS) Stacks Up Against Its Peers at Insider Monkey
Dec-06-16 01:11PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:00AM  Bio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting GlobeNewswire
Dec-01-16 08:40AM  Bio-Path Holdings, Inc. :BPTH-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-17-16 01:04PM  BIO-PATH HOLDINGS INC Financials -8.09%
Nov-10-16 07:11AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:00AM  Bio-Path Holdings Reports Third Quarter 2016 Financial Results GlobeNewswire
Nov-09-16 04:50PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report +10.00%
Nov-04-16 04:01PM  Bio-Path Holdings to Announce Third Quarter 2016 Financial Results on November 10, 2016 GlobeNewswire
01:42PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Bio-Path Holdings to Present Data at the 2016 ASH Annual Meeting GlobeNewswire
Nov-03-16 08:00AM  Bio-Path Announces Orphan Drug Designation in the European Union for BP1001 for the Treatment of Acute Myeloid Leukemia GlobeNewswire +5.62%
Nov-02-16 08:00AM  Bio-Path Holdings Announces First Patient Dosed in Phase 2 Trial Evaluating BP1001 in Acute Myeloid Leukemia GlobeNewswire
Sep-07-16 12:36PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-06-16 08:00AM  Bio-Path Holdings to Present at the Rodman & Renshaw 18th Annual Global Investment Conference GlobeNewswire
Aug-10-16 08:01AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:30AM  Bio-Path Holdings Reports Second Quarter 2016 Financial Results GlobeNewswire
06:38AM  Bio-Path reports 2Q loss
Aug-09-16 04:19PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report
Aug-03-16 08:00AM  Bio-Path Holdings to Announce Second Quarter 2016 Financial Results on August 10, 2016 GlobeNewswire
Aug-01-16 04:37PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exh
Jul-06-16 12:52PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure
08:00AM  Bio-Path Holdings to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference GlobeNewswire
Jul-01-16 06:05AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jun-30-16 06:10AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme
Jun-29-16 11:59AM  Bio-Path Holdings, Inc. Announces $10 Million Registered Direct Offering GlobeNewswire -10.05%
Jun-28-16 08:00AM  Bio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer GlobeNewswire
Jun-20-16 04:01PM  Bio-Path Holdings to Join Russell 3000® and Global Indexes GlobeNewswire
Jun-06-16 02:27PM  Bio-Path Holdings, Inc. :BPTH-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
12:41PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure
09:00AM  Bio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016 GlobeNewswire
May-20-16 02:51PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure
May-19-16 07:30AM  Bio-Path Holdings to Present Data at 2016 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-11-16 08:30AM  Bio Path Holdings Inc Earnings Call scheduled for 8:30 am ET today
07:46AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:39AM  Bio-Path reports 1Q loss
07:30AM  Bio-Path Holdings Reports First Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q1 2016 Bio Path Holdings Inc Earnings Release - Time Not Supplied
May-10-16 05:22PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report
09:45AM  Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More
May-05-16 03:45PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +5.18%
08:00AM  Bio-Path Holdings to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference GlobeNewswire
May-04-16 08:00AM  Bio-Path Holdings to Announce First Quarter 2016 Financial Results on May 11, 2016 GlobeNewswire
Apr-18-16 07:17AM  Coverage initiated on Bio-Path by Rodman & Renshaw
Apr-05-16 10:45AM  Stocks to Buy: Many Have Chosen These Today April 5th Accesswire -6.46%
Mar-24-16 02:16PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-23-16 08:55AM  Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with The University of Texas Southwestern Medical Center Business Wire
Mar-16-16 12:01PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition
09:09AM  Bio-Path reports 4Q loss
08:55AM  Bio-Path Holdings Reports Fiscal Year 2015 Operational and Financial Results Business Wire
Mar-15-16 04:30PM  BIO-PATH HOLDINGS INC Files SEC form 10-K, Annual Report
Mar-08-16 12:11PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:55AM  Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration with Leading Oncology Institution Business Wire
Mar-07-16 05:16PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure +6.92%
08:55AM  Bio-Path Holdings to Present at the 28th Annual ROTH Conference Business Wire
Mar-04-16 12:09PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure -14.05%
Mar-03-16 08:55AM  Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia Business Wire
Feb-01-16 01:59PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:55AM  Bio-Path Holdings to Present at the 18th Annual BIO CEO & Investor Conference Business Wire
Jan-13-16 05:26PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-06-16 02:40PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:55AM  Bio-Path Holdings to Present at Biotech Showcase 2016 Business Wire
Dec-30-15 02:11PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosu
Dec-08-15 02:51PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -7.54%
08:55AM  Bio-Path Holdings Data from Phase I and Safety Segment of Phase II Clinical Trials in Blood Cancers Presented at 57th American Society of Hematology (ASH) Annual Meeting Business Wire
Nov-10-15 04:26PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
09:03AM  Bio-Path reports 3Q loss
08:55AM  Bio-Path Holdings Reports Third Quarter 2015 Operational and Financial Results Business Wire
Nov-09-15 04:21PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report +5.59%
Nov-05-15 01:02PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:27AM  Bio-Path Holdings Data to be Presented at 57th American Society of Hematology (ASH) Annual Meeting Business Wire
Oct-14-15 03:50PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Oct-13-15 04:05PM  Bio-Path Holdings to Present at the 14th Annual BIO Investor Forum Business Wire
Oct-09-15 02:36PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +5.17%
08:55AM  Bio-Path Holdings Announces Successful Completion of Cohort 7 of Phase Ib Clinical Trial Evaluating Liposomal Grb-2 in Acute Myeloid Leukemia Business Wire
Sep-02-15 01:08PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:00AM  Bio-Path Holdings to Present at the 17th Annual Rodman & Renshaw Global Investment Conference Business Wire
Sep-01-15 12:16PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +7.27%
Aug-31-15 09:00AM  Bio-Path Holdings Forms Scientific Advisory Board to Support Advancement of Liposomal Grb-2 in Blood Cancers Business Wire
Aug-12-15 11:51AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
Aug-11-15 09:10AM  Bio-Path reports 2Q loss
09:00AM  Bio-Path Holdings Reports Second Quarter 2015 Operational and Financial Results Business Wire
Aug-10-15 04:23PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report
Jun-25-15 12:25PM  Bio-Path Holdings Announces At-the-Market Offering with Cantor Fitzgerald Business Wire
11:56AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibi
Jun-04-15 10:30AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Other Events
May-12-15 04:19PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition -5.08%
01:27PM  Bio-Path reports 1Q loss
01:05PM  Bio-Path Holdings Reports First Quarter 2015 Operational and Financial Results Business Wire
May-11-15 03:38PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report -5.60%
Apr-30-15 12:19PM  Bio-Path Holdings Appoints Tara Sadeghi As Director of Clinical Operations Business Wire -11.65%
Apr-29-15 06:15PM  Nasdaq stocks posting largest volume increases +29.41%
Apr-28-15 03:34PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
11:10AM  Bio-Path Holdings Granted Orphan Drug Designation for Liposomal Grb-2 in Acute Myeloid Leukemia Business Wire
Apr-24-15 12:04PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Apr-22-15 04:52PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +6.20%
08:30AM  Bio-Path Holdings Drug Delivery Technology to be Featured in a Presentation at IBCs 17th Annual TIDES Oligonucleotide and Peptide Therapeutics Conference Business Wire
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is Liposomal Grb2, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. The company was founded in 2007 and is based in Bellaire, Texas.